Announces IND Clearance for CDC7 Inhibitor SGR-2921, Continued Progress for MALT1 Inhibitor SGR-1505
Delivers Second Quarter Total Revenue of $35.2 Million
Raises 2023 Software Revenue Guidance and Reduces Drug Discovery Guidance
Schrödinger will host a conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023, at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. To access the call by phone, please dial 1-888-440-5983 (Toll-Free) or 1-646-960-0202 (Toll) and refer to conference ID 2440689. The archived webcast will be available on Schrödinger’s website for approximately 90 days following the event.
https://finance.yahoo.com/news/schr-dinger-reports-second-quarter-200000439.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.